Rezolute's FDA Pre-BLA Nod Sends Shares Soaring, But Can a Failed Trial Really Lead to an Approval?

Shares of Rezolute surged 11% to $4.45 after the FDA took the unusual step of recommending a pre-BLA meeting — essentially an invitation to discuss filing for approval — for the company's lead drug to treat congenital hyperinsulinism, a rare condition causing dangerously low blood sugar. The move is striking because the underlying clinical trial failed to hit its marks.

• The Trial Missed, But the FDA Didn't Walk Away. The Phase 3 study demonstrated glycemic improvements but did not meet its primary endpoint — reductions in hypoglycemia events by finger-stick blood glucose were not statistically significant compared to placebo.

The top dose showed a roughly 45% reduction in episodes, but placebo patients improved by 40%, washing out the difference. Normally a failed pivotal trial is a death sentence for a drug program. Yet at a March 2026 meeting, the FDA acknowledged the challenges posed by behavioral factors in clinical trials in this patient population. That concession kept the door open.

• A Pre-BLA Meeting Is Not a Green Light. The FDA has not taken a position on whether the drug can be approved, but its willingness to proceed to a pre-BLA discussion underscores the unmet need in congenital hyperinsulinism. Investors should understand this meeting is procedural — it lets Rezolute discuss what a formal application should contain. The real regulatory risk remains ahead.

• The Cash Clock Is Ticking. As of March 31, 2026, cash, cash equivalents, and investments stood at $120.3 million, down from $167.9 million at the end of fiscal 2025.

Full-year fiscal 2026 net loss was $77.6 million.

Rezolute has indicated its cash is sufficient for at least 12 months from March 2026, but additional financing will be needed to meet longer-term requirements. If FDA discussions drag or require new studies, a dilutive capital raise becomes likely.

• A Second Trial Could Strengthen — or Complicate — the Story. Rezolute plans to reassess its filing strategy once it reports topline results this quarter from a Phase 3 trial in tumor-related hyperinsulinism, which could support a broader regulatory package. Positive data there would give the FDA a second evidence base; another miss would likely devastate the stock. Multiple analysts recently raised price targets to $10, with Craig-Hallum upgrading shares to Buy.

At roughly $430 million in market value for a pre-revenue company running on hope and regulatory goodwill, RZLT is a high-conviction bet that the FDA will accept imperfect data for a disease with no approved treatment. The next quarter will tell.